DeepMed Research

Tocagen, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 2007-01-01

Employees: 51

Market Cap: -

Website: http://www.tocagen.com

Clinical Trials

A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511

Phase 1

Terminated

Conditions: Gliomas, Malignant
Glioblastoma Multiforme
Astrocytoma

Interventions: Biological: Toca 511 vector
Drug: Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine

First Posted Date: 2020-03-30

Last Posted Date: 2020-03-30

Lead Sponsor: Tocagen Inc.

Target Recruit Count: 65

Registration Number: NCT04327011

Locations: 🇺🇸
Swedish Neuroscience Institute, Seattle, Washington, United States
🇺🇸
UCSD, San Diego, California, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States

and more 8 locations

A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)

Phase 1

Withdrawn

Conditions: Bladder Cancer

Interventions: Biological: Toca 511
Drug: Toca FC (extended-release formulation of flucytosine)

First Posted Date: 2019-09-13

Last Posted Date: 2020-03-30

Lead Sponsor: Tocagen Inc.

Registration Number: NCT04089163

A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care

Phase 1

Withdrawn

Conditions: Newly Diagnosed High Grade Glioma (HGG)

Interventions: Biological: Toca 511
Drug: Toca FC

First Posted Date: 2015-11-05

Last Posted Date: 2020-03-30

Lead Sponsor: Tocagen Inc.

Registration Number: NCT02598011

A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)

Phase 1

Terminated

Conditions: Sarcoma
Triple Negative Breast Cancer
Ovarian Cancer
Bladder Cancer
Colorectal Cancer
Lymphoma
IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting)
Melanoma
IDH1 Mutated Solid Tumors
Pancreatic Cancer

Interventions: Biological: Toca 511
Drug: Toca FC

First Posted Date: 2015-10-15

Last Posted Date: 2020-02-07

Lead Sponsor: Tocagen Inc.

Target Recruit Count: 21

Registration Number: NCT02576665

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Sarah Cannon Research Institute, Denver, Colorado, United States

The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma

Phase 2

Terminated

Conditions: Glioblastoma Multiforme
Anaplastic Astrocytoma

Interventions: Biological: Toca 511
Drug: Lomustine
Drug: Toca FC
Drug: Temozolomide
Biological: Bevacizumab

First Posted Date: 2015-04-10

Last Posted Date: 2020-02-07

Lead Sponsor: Tocagen Inc.

Target Recruit Count: 403

Registration Number: NCT02414165

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸
University of Miami, Miami, Florida, United States

and more 64 locations

Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor

Phase 1

Completed

Conditions: Anaplastic Oligoastrocytoma
Glioblastoma Multiforme
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma

Interventions: Biological: Toca 511
Drug: Toca FC

First Posted Date: 2013-11-15

Last Posted Date: 2018-05-21

Lead Sponsor: Tocagen Inc.

Target Recruit Count: 17

Registration Number: NCT01985256

Locations: 🇺🇸
JFK Medical Center New Jersery, Edison, New Jersey, United States
🇺🇸
UC Irivine, Irvine, California, United States
🇺🇸
UCLA, Los Angeles, California, United States

and more 3 locations

Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor

Phase 1

Completed

Conditions: Anaplastic Oligodendroglioma
Glioblastoma Multiforme
Anaplastic Astrocytoma
Anaplastic Oligoastrocytoma

Interventions: Biological: Toca 511 vector
Drug: Toca FC

First Posted Date: 2011-11-11

Last Posted Date: 2018-05-21

Lead Sponsor: Tocagen Inc.

Target Recruit Count: 58

Registration Number: NCT01470794

Locations: 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States

and more 5 locations

A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma

Phase 1

Completed

Conditions: Glioblastoma
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Anaplastic Oligoastrocytoma

Interventions: Biological: Toca 511 vector
Drug: Toca FC

First Posted Date: 2010-07-05

Last Posted Date: 2018-05-21

Lead Sponsor: Tocagen Inc.

Target Recruit Count: 54

Registration Number: NCT01156584

Locations: 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸
UCSD, San Diego, California, United States
🇺🇸
UCSF, San Francisco, California, United States

and more 7 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy